NAPOLI 3, POUT, & Ivosidenib - Azole DDIs
OncoPharm
by John Bossaer
5d ago
New updates on metastatic pancreatic cancer (NAPOLI-3), upper tract urothelial cancer (POUT), and the drug-drug interaction between ivosidenib and azole antifungals. NAPOLI 3: https://doi.org/10.1016/S0140-6736(23)01366-1 POUT (final OS): https://doi.org/10.1200/JCO.23.01659 Ivosidenib Azole Antifungal DDIs: https://doi.org/10.1002/cncr.35251 ..read more
Visit website
Small Cell Carcinoma, Prostate Edition
OncoPharm
by John Bossaer
2w ago
You know about small cell lung cancer, but let's talk about small cell carcinoma of the prostate ..read more
Visit website
Rethinking Some Fundamental Considerations
OncoPharm
by John Bossaer
3w ago
In oncology we are always asking questions about which treatment option is best. And that focus on the next best treatment may prevent us from rethinking some fundamentals of current practice. Three recent studies illustrate this and made me ask: Do we need a Port or PICC for every testicular cancer patient? Study: https://doi.org/10.1200/OP.23.00580 Editorial: https://doi.org/10.1200/OP.23.00730 Is vaginal estrogen safe if breast cancer patients? Study: https://jamanetwork.com/journals/jamaoncology/article-abstract/2811413 Does paclitaxel work differently than we always thought? Study: https ..read more
Visit website
Jan 2024 Updates...
OncoPharm
by John Bossaer
3w ago
on FDA approvals for belzutifan for RCC, pembrolizumab + cisplatin/RT for cervical cancer, erdafitinib (FGFR3 alterations only) for bladder cancer. Plus, early morning ICIs (https://doi.org/10.1016/j.ejca.2024.113571) & FLAG-Ida-GO in AML from NCRI AML 19 (https://doi.org/10.1200/JCO.23.00943 ..read more
Visit website
Development Of Generic Lenalidomide with Dr. Ryan Beechinor
OncoPharm
by John Bossaer
1M ago
Special guest Ryan Beechinor joins the pod to discuss his recent paper on the obstacles in the development of generic lenalidomide. It's a fantastic read, and this episode will be a fantastic listen! Link: https://doi.org/10.1016/j.jcpo.2023.100446 ..read more
Visit website
Lenalidomide
OncoPharm
by John Bossaer
1M ago
Foundations of OncoPharm episode on lenalidomide (Revlimid) and its MOA, use, dosing, & toxicity ..read more
Visit website
2023 New Drug Review
OncoPharm
by John Bossaer
2M ago
A Holiday Tradition returns as we review 14 new OncoPharm drugs approved this past year and ask Keep, Re-Gift, or Return ..read more
Visit website
ASH23 Appetizers
OncoPharm
by John Bossaer
2M ago
Small bites of updates coming out of ASH's 2023 annual meeting on CLL, multiple myeloma, and lymphoma ..read more
Visit website
VISTA
OncoPharm
by John Bossaer
2M ago
Our Landmarks of OncoPharm series returns to talk about 2008's VISTA study, which ushered bortezomib into the front line setting, albeit with a now outdated alkylating agent-based backbone. VISTA (VMP vs. MP): https://www.nejm.org/doi/full/10.1056/nejmoa0801479 ..read more
Visit website
Gamma Secretase Inhibition et al
OncoPharm
by John Bossaer
3M ago
The recent approval of nirogacestat, the first gamma secretase inhibitor on the market, provides a great opportunity to discuss desmoid tumors and Notch signaling. Review article: https://doi.org/10.1002/onco.13627 Also, a new T-cell malignancy warning for most CAR-T products. And, is belantamab mafodotin coming back based on the DREAMM-7 results ..read more
Visit website

Follow OncoPharm on FeedSpot

Continue with Google
Continue with Apple
OR